Profusa shares surge 34.13% premarket after receiving purchase orders for Lumee™ and raising 2026 revenue guidance.

Profusa Inc. (PFSA) surged 34.13% in premarket trading following the announcement that it received purchase orders for its Lumee™ Tissue Oxygen Monitoring system and raised its 2026 revenue guidance. The news, reported by GlobeNewswire six days prior, highlights growing demand for the company’s oxygen monitoring technology and reinforces its commercialization progress. Additional recent developments, including a collaboration with Mayo Clinic, a reverse stock split, and clinical trial updates, have further bolstered investor confidence. However, the most immediate catalyst appears to be the revenue guidance upgrade and new purchase orders, signaling strong market traction for its core product. The stock’s sharp premarket rise aligns with positive momentum from these operational and financial advancements.